OmniAb (OABI) Operating Expenses (2021 - 2026)
OmniAb (OABI) posted quarterly Operating Expenses of $22.3 million for Q1 2026, down 3.23% year-over-year from $23.0 million in Q1 2025, and down 7.81% quarter-over-quarter from $24.1 million in Q4 2025.
OmniAb (OABI) Operating Expenses (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Operating Expenses for 6 consecutive years, with $22.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 3.23% year-over-year to $22.3 million; the TTM figure through Mar 2026 stood at $86.9 million (down 10.91% YoY), while the FY2025 annual figure was $87.6 million, down 13.14% from the prior year.
- Operating Expenses fell to $22.3 million in Q1 2026 per OABI's latest filing, from $24.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $26.7 million in Q4 2024 and bottomed at $17.8 million in Q1 2022.
- Historically, Operating Expenses has averaged $23.5 million across 5 years, with a median of $23.9 million in 2024.
- On a YoY basis, Operating Expenses climbed as much as 904476.66% in 2022 and fell as far as 62.53% in 2022.
- OmniAb's Operating Expenses stood at $26.3 million in 2022, then dropped by 1.02% to $26.0 million in 2023, then rose by 2.52% to $26.7 million in 2024, then slipped by 9.53% to $24.1 million in 2025, then retreated by 7.81% to $22.3 million in 2026.
- Business Quant data shows OABI's Operating Expenses at $22.3 million in Q1 2026, $24.1 million in Q4 2025, and $20.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 20.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.05 Mn |
| Mar 31, 2026 | 22.26 Mn |
| Dec 31, 2025 | 24.14 Mn |
| Sep 30, 2025 | 20.38 Mn |
| Jun 30, 2025 | 20.12 Mn |
| Mar 31, 2025 | 23.00 Mn |
| Dec 31, 2024 | 26.68 Mn |
| Sep 30, 2024 | 23.94 Mn |
| Jun 30, 2024 | 23.92 Mn |
| Mar 31, 2024 | 26.35 Mn |
| Dec 31, 2023 | 26.03 Mn |
| Sep 30, 2023 | 25.79 Mn |
| Jun 30, 2023 | 26.39 Mn |
| Mar 31, 2023 | 25.37 Mn |
| Dec 31, 2022 | 26.30 Mn |
| Sep 30, 2022 | 21.82 Mn |
| Jun 30, 2022 | 19.77 Mn |
| Mar 31, 2022 | 17.85 Mn |
| Dec 31, 2021 | 70.18 Mn |
| Sep 30, 2021 | 170,579.00 |